Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model

Zebin Hu, Janhavi Gupta, Zhenwei Zhang, Helen Gerseny, Arthur Berg, Yun Ju Chen, Zhiling Zhang, Hongyan Du, Charles B. Brendler, Xianghui Xiao, Kenneth J. Pienta, Theresa Guise, Chung Lee, Paula H. Stern, Stuart Stock, Prem Seth

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We have examined whether Ad.sTβRFc and TAd.sTβRFc, two oncolytic viruses expressing soluble transforming growth factor-β receptor II fused with human Fc (sTGFβRIIFc), can be developed to treat bone metastasis of prostate cancer. Incubation of PC-3 and DU-145 prostate tumor cells with Ad.sTβRFc and TAd.sTβRFc produced sTGFβRIIFc and viral replication; sTGFβRIIFc caused inhibition of TGF-β-mediated SMAD2 and SMAD3 phosphorylation. Ad(E1-).sTβRFc, an E1- adenovirus, produced sTGFβRIIFc but failed to replicate in tumor cells. To examine the antitumor response of adenoviral vectors, PC-3-luc cells were injected into the left heart ventricle of nude mice. On day 9, mice were subjected to whole-body bioluminescence imaging (BLI). Mice bearing hind-limb tumors were administered viral vectors via the tail vein on days 10, 13, and 17 (2.5×10 10 viral particles per injection per mouse, each injection in a 0.1-ml volume), and subjected to BLI and X-ray radiography weekly until day 53. Ad.sTβRFc, TAd.sTβRFc, and Ad(E1-).sTβRFc caused significant inhibition of tumor growth; however, Ad.sTβRFc was the most effective among all the vectors. Only Ad.sTβRFc and TAd.sTβRFc inhibited tumor-induced hypercalcemia. Histomorphometric and synchrotron micro-computed tomographic analysis of isolated bones indicated that Ad.sTβRFc induced significant reduction in tumor burden, osteoclast number, and trabecular and cortical bone destruction. These studies suggest that Ad.sTβRFc and TAd.sTβRFc can be developed as potential new therapies for prostate cancer bone metastasis.

Original languageEnglish
Pages (from-to)871-882
Number of pages12
JournalHuman Gene Therapy
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Transforming Growth Factors
Adenoviridae
Growth Factor Receptors
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Neoplasms
Heart Ventricles
Oncolytic Viruses
Whole Body Imaging
Bone Neoplasms
Injections
Synchrotrons
Hypercalcemia
Osteoclasts
Tumor Burden
Nude Mice
Radiography
Virion
Tail

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. / Hu, Zebin; Gupta, Janhavi; Zhang, Zhenwei; Gerseny, Helen; Berg, Arthur; Chen, Yun Ju; Zhang, Zhiling; Du, Hongyan; Brendler, Charles B.; Xiao, Xianghui; Pienta, Kenneth J.; Guise, Theresa; Lee, Chung; Stern, Paula H.; Stock, Stuart; Seth, Prem.

In: Human Gene Therapy, Vol. 23, No. 8, 01.08.2012, p. 871-882.

Research output: Contribution to journalArticle

Hu, Z, Gupta, J, Zhang, Z, Gerseny, H, Berg, A, Chen, YJ, Zhang, Z, Du, H, Brendler, CB, Xiao, X, Pienta, KJ, Guise, T, Lee, C, Stern, PH, Stock, S & Seth, P 2012, 'Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model', Human Gene Therapy, vol. 23, no. 8, pp. 871-882. https://doi.org/10.1089/hum.2012.040
Hu, Zebin ; Gupta, Janhavi ; Zhang, Zhenwei ; Gerseny, Helen ; Berg, Arthur ; Chen, Yun Ju ; Zhang, Zhiling ; Du, Hongyan ; Brendler, Charles B. ; Xiao, Xianghui ; Pienta, Kenneth J. ; Guise, Theresa ; Lee, Chung ; Stern, Paula H. ; Stock, Stuart ; Seth, Prem. / Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. In: Human Gene Therapy. 2012 ; Vol. 23, No. 8. pp. 871-882.
@article{01daebec29dc465b9ed2bd42cbd9cc25,
title = "Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model",
abstract = "We have examined whether Ad.sTβRFc and TAd.sTβRFc, two oncolytic viruses expressing soluble transforming growth factor-β receptor II fused with human Fc (sTGFβRIIFc), can be developed to treat bone metastasis of prostate cancer. Incubation of PC-3 and DU-145 prostate tumor cells with Ad.sTβRFc and TAd.sTβRFc produced sTGFβRIIFc and viral replication; sTGFβRIIFc caused inhibition of TGF-β-mediated SMAD2 and SMAD3 phosphorylation. Ad(E1-).sTβRFc, an E1- adenovirus, produced sTGFβRIIFc but failed to replicate in tumor cells. To examine the antitumor response of adenoviral vectors, PC-3-luc cells were injected into the left heart ventricle of nude mice. On day 9, mice were subjected to whole-body bioluminescence imaging (BLI). Mice bearing hind-limb tumors were administered viral vectors via the tail vein on days 10, 13, and 17 (2.5×10 10 viral particles per injection per mouse, each injection in a 0.1-ml volume), and subjected to BLI and X-ray radiography weekly until day 53. Ad.sTβRFc, TAd.sTβRFc, and Ad(E1-).sTβRFc caused significant inhibition of tumor growth; however, Ad.sTβRFc was the most effective among all the vectors. Only Ad.sTβRFc and TAd.sTβRFc inhibited tumor-induced hypercalcemia. Histomorphometric and synchrotron micro-computed tomographic analysis of isolated bones indicated that Ad.sTβRFc induced significant reduction in tumor burden, osteoclast number, and trabecular and cortical bone destruction. These studies suggest that Ad.sTβRFc and TAd.sTβRFc can be developed as potential new therapies for prostate cancer bone metastasis.",
author = "Zebin Hu and Janhavi Gupta and Zhenwei Zhang and Helen Gerseny and Arthur Berg and Chen, {Yun Ju} and Zhiling Zhang and Hongyan Du and Brendler, {Charles B.} and Xianghui Xiao and Pienta, {Kenneth J.} and Theresa Guise and Chung Lee and Stern, {Paula H.} and Stuart Stock and Prem Seth",
year = "2012",
month = "8",
day = "1",
doi = "10.1089/hum.2012.040",
language = "English",
volume = "23",
pages = "871--882",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model

AU - Hu, Zebin

AU - Gupta, Janhavi

AU - Zhang, Zhenwei

AU - Gerseny, Helen

AU - Berg, Arthur

AU - Chen, Yun Ju

AU - Zhang, Zhiling

AU - Du, Hongyan

AU - Brendler, Charles B.

AU - Xiao, Xianghui

AU - Pienta, Kenneth J.

AU - Guise, Theresa

AU - Lee, Chung

AU - Stern, Paula H.

AU - Stock, Stuart

AU - Seth, Prem

PY - 2012/8/1

Y1 - 2012/8/1

N2 - We have examined whether Ad.sTβRFc and TAd.sTβRFc, two oncolytic viruses expressing soluble transforming growth factor-β receptor II fused with human Fc (sTGFβRIIFc), can be developed to treat bone metastasis of prostate cancer. Incubation of PC-3 and DU-145 prostate tumor cells with Ad.sTβRFc and TAd.sTβRFc produced sTGFβRIIFc and viral replication; sTGFβRIIFc caused inhibition of TGF-β-mediated SMAD2 and SMAD3 phosphorylation. Ad(E1-).sTβRFc, an E1- adenovirus, produced sTGFβRIIFc but failed to replicate in tumor cells. To examine the antitumor response of adenoviral vectors, PC-3-luc cells were injected into the left heart ventricle of nude mice. On day 9, mice were subjected to whole-body bioluminescence imaging (BLI). Mice bearing hind-limb tumors were administered viral vectors via the tail vein on days 10, 13, and 17 (2.5×10 10 viral particles per injection per mouse, each injection in a 0.1-ml volume), and subjected to BLI and X-ray radiography weekly until day 53. Ad.sTβRFc, TAd.sTβRFc, and Ad(E1-).sTβRFc caused significant inhibition of tumor growth; however, Ad.sTβRFc was the most effective among all the vectors. Only Ad.sTβRFc and TAd.sTβRFc inhibited tumor-induced hypercalcemia. Histomorphometric and synchrotron micro-computed tomographic analysis of isolated bones indicated that Ad.sTβRFc induced significant reduction in tumor burden, osteoclast number, and trabecular and cortical bone destruction. These studies suggest that Ad.sTβRFc and TAd.sTβRFc can be developed as potential new therapies for prostate cancer bone metastasis.

AB - We have examined whether Ad.sTβRFc and TAd.sTβRFc, two oncolytic viruses expressing soluble transforming growth factor-β receptor II fused with human Fc (sTGFβRIIFc), can be developed to treat bone metastasis of prostate cancer. Incubation of PC-3 and DU-145 prostate tumor cells with Ad.sTβRFc and TAd.sTβRFc produced sTGFβRIIFc and viral replication; sTGFβRIIFc caused inhibition of TGF-β-mediated SMAD2 and SMAD3 phosphorylation. Ad(E1-).sTβRFc, an E1- adenovirus, produced sTGFβRIIFc but failed to replicate in tumor cells. To examine the antitumor response of adenoviral vectors, PC-3-luc cells were injected into the left heart ventricle of nude mice. On day 9, mice were subjected to whole-body bioluminescence imaging (BLI). Mice bearing hind-limb tumors were administered viral vectors via the tail vein on days 10, 13, and 17 (2.5×10 10 viral particles per injection per mouse, each injection in a 0.1-ml volume), and subjected to BLI and X-ray radiography weekly until day 53. Ad.sTβRFc, TAd.sTβRFc, and Ad(E1-).sTβRFc caused significant inhibition of tumor growth; however, Ad.sTβRFc was the most effective among all the vectors. Only Ad.sTβRFc and TAd.sTβRFc inhibited tumor-induced hypercalcemia. Histomorphometric and synchrotron micro-computed tomographic analysis of isolated bones indicated that Ad.sTβRFc induced significant reduction in tumor burden, osteoclast number, and trabecular and cortical bone destruction. These studies suggest that Ad.sTβRFc and TAd.sTβRFc can be developed as potential new therapies for prostate cancer bone metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84865237178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865237178&partnerID=8YFLogxK

U2 - 10.1089/hum.2012.040

DO - 10.1089/hum.2012.040

M3 - Article

C2 - 22551458

AN - SCOPUS:84865237178

VL - 23

SP - 871

EP - 882

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 8

ER -